Cargando…
Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive inve...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637339/ https://www.ncbi.nlm.nih.gov/pubmed/34867972 http://dx.doi.org/10.3389/fimmu.2021.745769 |
_version_ | 1784608722520113152 |
---|---|
author | Zhang, Zhihui Wu, Peng Zhang, Chaoqi Luo, Yuejun Zhang, Guochao Zeng, Qingpeng Wang, Lide Yang, Zhaoyang Sun, Nan He, Jie |
author_facet | Zhang, Zhihui Wu, Peng Zhang, Chaoqi Luo, Yuejun Zhang, Guochao Zeng, Qingpeng Wang, Lide Yang, Zhaoyang Sun, Nan He, Jie |
author_sort | Zhang, Zhihui |
collection | PubMed |
description | Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management. |
format | Online Article Text |
id | pubmed-8637339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86373392021-12-03 Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer Zhang, Zhihui Wu, Peng Zhang, Chaoqi Luo, Yuejun Zhang, Guochao Zeng, Qingpeng Wang, Lide Yang, Zhaoyang Sun, Nan He, Jie Front Immunol Immunology Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management. Frontiers Media S.A. 2021-11-18 /pmc/articles/PMC8637339/ /pubmed/34867972 http://dx.doi.org/10.3389/fimmu.2021.745769 Text en Copyright © 2021 Zhang, Wu, Zhang, Luo, Zhang, Zeng, Wang, Yang, Sun and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Zhihui Wu, Peng Zhang, Chaoqi Luo, Yuejun Zhang, Guochao Zeng, Qingpeng Wang, Lide Yang, Zhaoyang Sun, Nan He, Jie Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title | Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title_full | Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title_fullStr | Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title_full_unstemmed | Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title_short | Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer |
title_sort | tumor necrosis factor family member profile predicts prognosis and adjuvant chemotherapy benefit for patients with small-cell lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637339/ https://www.ncbi.nlm.nih.gov/pubmed/34867972 http://dx.doi.org/10.3389/fimmu.2021.745769 |
work_keys_str_mv | AT zhangzhihui tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT wupeng tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT zhangchaoqi tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT luoyuejun tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT zhangguochao tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT zengqingpeng tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT wanglide tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT yangzhaoyang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT sunnan tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT hejie tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer |